
BioDrugs Journal
@biodrugsjournal
BioDrugs (2023 IF 5.4) covers the development and therapeutic application of biotechnology-based pharmaceuticals for the treatment of human disease.
ID: 123826772
https://www.springer.com/journal/40259 17-03-2010 09:58:20
298 Tweet
74 Followers
27 Following





Findings from a targeted review have been incorporated into a framework of biosimilar market sustainability dimensions, to be used by stakeholders in decision-making to ensure long-term viability of the market. #Biosimilar #biosimilarmarket #sustainability link.springer.com/article/10.100…

Structure activity relationship studies of the biosimilar BAT1806/BIIB800 and reference tocilizumab were conducted to assess the potential impact of observed minor differences in quality attributes #biosimilarity #Structureactivity #Tocilizumab #openaccess link.springer.com/article/10.100…




This study investigated the clinical safety, tolerability, pharmacokinetics & preliminary pharmacodynamics of HEC88473, a 2nd generation GLP-1/FGF21 agonist, in a phase I, single-ascending dose trial with healthy & obese subjects #glp1 #FGF21 #FirstInHuman link.springer.com/article/10.100…

In this cohort study of older patients with immune-mediated inflammatory diseases, Gianluca Trifirò et al found a 6-fold increase in use of biologics from 2010 to 2022, and a treatment persistence of ~50% at one year. #OpenAccess #biologics #olderadults link.springer.com/article/10.100…








